Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound according to general formula 1, or a pharmaceutically acceptable salt thereof,



1

wherein

R^1 is selected from H, lower alkyl, R^4-CO, R^4-O_2CCH_2, R^5-OCO and R^5-SO_2;

R^2 is selected from lower alkyl, cycloalkyl optionally substituted with an alkyl or alkyloxy group, (C_5-C_{12})cycloalkylalkyl optionally substituted with an alkyl or alkyloxy group, aralkyl optionally substituted with up to three groups chosen from F, Cl, Br, I, OH, lower alkyl, O-(lower alkyl), O-benzyl, NH_2, NO_2, NH-acyl, CN and CF_3, and aralkyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); or

R^1 and R^2 together <u>form</u>[[are]] an *o*-xylylene group <u>wherein the aromatic ring moiety of the *o*-xylylene group is</u> optionally substituted ~~on the aromatic ring~~ with a group selected from F, Cl, Br, OH, lower alkyl and O-(lower alkyl);

R^3 is selected from H, OH and O-lower alkyl;

R^4 is selected from H, lower alkyl and phenyl; and

R^5 is selected from lower alkyl, phenyl and benzyl.

2. (Original) A compound according to Claim 1 wherein R^1 is selected from H, lower alkyl, and R^4-O_2CCH_2.

3. (Previously Presented) A compound according to Claim 1 wherein R^2 is selected from (C_6-C_{10})cycloalkylmethyl, benzyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl), phenethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl)and benzyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl).

4. (Previously Presented) A compound according to Claim 1 wherein R^2 is selected from cyclohexylmethyl, decahydronaphth-2-ylmethyl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 4-(lower alkyl)oxybenzyl, α-hydroxybenzyl, α-methoxybenzyl, phenethyl and benzyloxymethyl.

5. (Previously Presented) A compound according to Claim 1 wherein the absolute stereochemistry is as depicted in general formula 1A.



1A

6. (Previously Presented) A compound according to Claim 1 wherein the absolute stereochemistry is as depicted in general formula 1B.



1B

7. (Previously Presented) A compound according to Claim 1 selected from

(2'*S*,2"*R*)-4-(2'-(2"-amino-3"-(4"'-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-carboxymethylamino-3"-(4"'-ethoxyphenyl)propanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(3"-(4"'-ethoxyphenyl)-2"-(methyloxycarbonylmethylamino)-propanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-amino-3"-cyclohexylpropanoylamino)-3'-phenylpropanoyl-amino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-carboxymethylamino-3"-cyclohexylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(3"-cyclohexyl-2"-(methyloxycarbonylmethylamino)propanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-amino-3"-phenylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-carboxymethylamino-3"-phenylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-(methyloxycarbonylmethylamino)-3"-phenylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-amino-3"-decahydronaphth-2"'-ylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(2"-carboxymethylamino-3"-decahydronaphth-2"'-ylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*)-4-(2'-(3"-decahydronaphth-2"'-yl-2"-(methyloxycarbonylmethylamino)-propanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*,3'*R*)-4-(2'-(2"-amino-3"-cyclohexylpropanoylamino)-3'-hydroxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*,3'*R*)-4-(2'-(2"-carboxymethylamino-3"-cyclohexylpropanoylamino)-3'-hydroxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*,3'*R*)-4-(2'-(3"-cyclohexyl-2"-(methyloxycarbonylmethylamino)propanoylamino)-3'-hydroxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*,3'*R*)-4-(2'-(2"-amino-3"-(4"'-ethoxyphenyl)propanoylamino)-3'-methoxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine;

(2'*S*,2"*R*,3'*R*)-4-(2'-(2"-carboxymethylamino-3"-(4"'-ethoxyphenyl)propanoylamino)-3'-methoxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine; and

(2'*S*,2"*R*,3'*R*)-4-(2'-(3"-(4"'-ethoxyphenyl)-2"-(methyloxycarbonylmethylamino)-propanoylamino)-3'-methoxy-3'-phenylpropanoylamino)piperidine-1-carboxamidine

or a pharmaceutically acceptable salt thereof.

8. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

9. (Withdrawn-Currently Amended) A method of treatment of a disease condition for which over activity of plasma kallikrein is a causative factor comprising administration to a patient in need thereof of a pharmaceutically active amount of compound of general formula 1, or a pharmaceutically acceptable salt thereof,



1

wherein

R^1 is selected from H, lower alkyl, R^4-CO, R^4-O_2CCH_2, R^5-OCO and R^5-SO_2;

R^2 is selected from lower alkyl, cycloalkyl optionally substituted with an alkyl or alkyloxy group, (C_5-C_{12})cycloalkylalkyl optionally substituted with an alkyl or alkyloxy group, aralkyl optionally substituted with up to three groups chosen from F, Cl, Br, I, OH, lower alkyl, O-(lower alkyl), O-benzyl, NH_2, NO_2, NH-acyl, CN and CF_3, and aralkyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); or

R^1 and R^2 together form[[are]] an *o*-xylylene group wherein the aromatic ring moiety of the xylylene group is optionally substituted ~~on the aromatic ring~~ with a group selected from F, Cl, Br, OH, lower alkyl and O-(lower alkyl);

R^3 is selected from H, OH and O-lower alkyl;

R^4 is selected from H, lower alkyl and phenyl; and

R^5 is selected from lower alkyl, phenyl and benzyl;

wherein the disease condition is selected from the group consisting of inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery, and bleeding from post-operative surgery.

10-11. (Canceled.)

12. (Currently Amended) The[[A]] pharmaceutical composition according to Claim 8 comprising an amount of the compound according to Claim 1 or a pharmaceutically

acceptable salt therof for the treatment of ~~a disease condition for which over activity of plasma kallikrein is a causative factor~~ a disease condition selected from the group consisting of inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post-operative surgery.